LYL273 for Patients With Relapsed or Refractory mCRC
Study sponsor: Lyell Immunopharma, Inc. · LYEL
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2028-06Estimated
Enrollment · participants155Estimated
Source updated2026-10-30Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.